Key Stats for GE Healthcare Stock
- Past-Week Performance: +0.05%
- 52-Week Range: $57.7 to $87.8
- Current Price: $80.2
What Happened?
GEHC‘s innovation pipeline is forcing a reframe: the stock at $80.16 reflects a company mid-transformation, not a mature medical device name coasting on installed base.
On February 19, the FDA granted 510(k) clearance for three MRI systems simultaneously: SIGNA Sprint with Freelium, SIGNA Bolt, and SIGNA One, accelerating GEHC’s push into next-generation imaging.
PDx organic growth hit 12.7% in Q4, and Flyrcado reached 220 weekly doses by January 23, directly supporting management’s $500 million revenue target by year-end 2028.
Peter Arduini, President and CEO, stated on the Q4 earnings call that “our confidence in our ability to deliver $500 million or more in Flyrcado revenue by year-end 2028 remains intact,” aligning directly with the February 17 BARDA expansion awarding GEHC roughly $35 million to advance AI-powered ultrasound.
Furthermore, the new $500 million revolving credit facility signed February 26 with JPMorgan signals balance sheet readiness to fund the Intelerad close, a deal adding $270 million in high-margin, low-double-digit-growth SaaS revenue to a portfolio already targeting $1.8 billion in digital revenue.
Wall Street’s Take on GEHC Stock
The FDA’s February 19 clearance of three MRI systems simultaneously confirms GEHC’s innovation pipeline is converting R&D investment into approved, revenue-generating products ahead of the 2027 acceleration cycle.
Consensus estimates project revenue reaching $21.6 billion in 2026, growing 4.9% YoY, while EPS climbs 10.1% to $5.06, extending a trajectory that saw EBITDA margins compress only modestly to 18.1% in 2025 before recovering to 18.5%.
Wall Street currently shows 11 buys, 3 outperforms, 6 holds, and 1 sell, with a mean price target of $93.25, implying 16.3% upside from the March 2 close of $80.16, with analysts holding conviction through a pullback rather than chasing momentum.
The analyst target range spans $75.00 on the low end to $110.00 on the high end, where the low hinges on China continuing to drag and tariff mitigation stalling, while the high requires Photonova approval, Intelerad closing cleanly, and Flyrcado doses scaling materially through mid-2026.
What Does the Valuation Model Say?
The TIKR valuation model targets $109.71 by December 31, 2030, implying 36.9% total return and a 6.7% IRR from current levels, a gap the market has yet to price in.
The market is treating GEHC like a slow-growth device company, yet its PDx segment alone grew organically 12.7% in Q4.
The Intelerad acquisition adds $270 million in SaaS revenue growing low double digits, a recurring revenue profile the stock’s current multiple does not yet reflect.
Management’s Heartbeat system already drove a 25% monthly improvement in past-due backlog, signaling operational leverage that consensus margin estimates likely underestimate.
China budgeted down in 2026 combined with a Q1 tariff peak could compress near-term EPS below the $5.06 consensus if mitigation efforts stall, putting the 8% to 12% full-year growth guide at risk.
Flyrcado’s weekly dose trajectory through Q2 will determine whether the $500 million 2028 revenue target remains credible and whether PDx sustains double-digit organic growth.
GEHC trades as undervalued at $80.16, with a pipeline-driven earnings reacceleration in 2027 and a model-implied target of $109.71 making the current price a patient entry point.
Should You Invest in GE Healthcare Technologies, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up GEHC stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track GE Healthcare Technologies, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze GEHC stock on TIKR for Free →
